Universities and research institutes at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

53 universities and research institutes are at ISLB 2026 — 96 presentations on the program. Most represented: National and Kapodistrian University of Athens (5 on the program), University of Naples Federico II (4 on the program), CIMA University of Navarra (4 on the program). 29 of them have their own page in this guide. As of Oct 16, 2026.

All 160 organizations at ISLB 2026 →

Showing 1–9 of 53 organizations

Organization	ISLB 2026 Attendance
National and Kapodistrian University of Athens Athens, Greece
uoa.gr Universities & research institutes Public university in Athens, Greece, with schools of medicine and science.	Talk Sun Nov 8 3:45pm–5:15pm Part of Awards Lecture The Evolving Landscape of CTCs in Precision Oncology: A Marathon Race Worth Running Talk Mon Nov 9 10:00am–11:30am Part of Preferred Oral Abstract Session Ultra-sensitive Detection of BRAF V600E in Plasma cfDNA of Early-stage Melanoma patients based on PD UV-ME ddPCR Poster Part of Poster sessions Droplet Digital PCR Analysis in Size-based Enriched Circulating Tumor Cells Reveals Unique ESR1 Subclonal Heterogeneity Missing in Plasma Cell-free DNA New analytes Poster Part of Poster sessions A Multi Cancer Basket Trial Evaluating Overexpression of PD-L1 mRNA in CTCs as a Predictive Biomarker for Response to Immunotherapy Clinical use · New analytes Poster Part of Poster sessions Liquid Biopsy EGFR Testing: Real-world Multicenter Experience in Greece Clinical use
University of Naples Federico II Naples, Italy
unina.it Universities & research institutes Public university in Naples, Italy, with a school of medicine and a teaching hospital.	Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Identifying Educational Needs to Support Personalized Medicine Approaches in Cancer (SPARC): Preliminary Results from the Work Package 6 Survey Collaborators: Universidad Politécnica de Madrid Industry Sun Nov 8 8:15am–9:15am Part of Enabling Precision Oncology: The Expanding Role of Liquid Biopsy Across Solid Tumors From Diagnosis to Disease Monitoring: The Expanding Role of Liquid Biopsy Across Solid Tumours Industry hosted by AstraZeneca and Thermo Fisher Scientific Clinical use Industry Sun Nov 8 8:15am–9:15am Part of Enabling Precision Oncology: The Expanding Role of Liquid Biopsy Across Solid Tumors Panel Discussion and Q&A Industry hosted by AstraZeneca and Thermo Fisher Scientific Clinical use Session Sun Nov 8 9:30am–11:00am Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures New analytes Talk Sun Nov 8 9:30am–11:00am Part of Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures Proteomics in Liquid Biopsy: The Future is Here? New analytes Industry Sun Nov 8 12:15pm–1:15pm Part of ESR1 Testing in Liquid Biopsy: From Laboratory Excellence to Confident Clinical Decisions Opening and Introduction Industry hosted by Menarini Stemline Clinical use · Pre-analytics Industry Sun Nov 8 12:15pm–1:15pm Part of ESR1 Testing in Liquid Biopsy: From Laboratory Excellence to Confident Clinical Decisions Clinical Cases Panel Discussion and Q&A Industry hosted by Menarini Stemline Clinical use · Pre-analytics Session Sun Nov 8 3:45pm–5:15pm Awards Lecture Talk Sun Nov 8 5:30pm–6:30pm Part of Young Career Session The Evolving Landscape of Next-generation Sequencing in Liquid Biopsy Industry Mon Nov 9 8:00am–9:00am Part of From Plasma to Practice: Longitudinal Insights for Breast and Lung Cancer Welcome, Framing, and Objectives Industry hosted by Guardant Health Clinical use · ctDNA & MRD Industry Mon Nov 9 8:00am–9:00am Part of From Plasma to Practice: Longitudinal Insights for Breast and Lung Cancer Panel Discussion & Live Q&A: What Makes a Longitudinal Liquid-Biopsy Result Actionable? Industry hosted by Guardant Health Clinical use · ctDNA & MRD Talk Mon Nov 9 10:00am–11:30am Part of Preferred Oral Abstract Session Identifying Educational Needs to Support Personalized Medicine Approaches in Cancer (SPARC): Preliminary Results from the Work Package 6 Survey Poster Part of Poster sessions Technical Feasibility of a Digital Solid PCR Platform Multiplexing ESR1 Activating Mutation in Real-world Liquid Biopsy Samples ctDNA & MRD · New analytes Collaborators: QIAGEN
CIMA University of Navarra Pamplona, Spain
cima.cun.es Universities & research institutes Applied medical research centre of the University of Navarra, with a solid tumours programme.	Talk Sat Nov 7 9:45am–11:15am Part of Evolving and Future Methodologies in Liquid Biopsy: CTCs, Tumor Vesicles and Emerging Approaches Multimodal Liquid Biopsy in SCLC New analytes Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Session Sat Nov 7 4:00pm–5:30pm Workshop Biological Fluids: Pre-analytical Issues Pre-analytics Poster Part of Poster sessions Novel Cytokine-based Liquid Biopsy Biomarkers Related to Response and Survival in SCLC Patients Treated with Chemoimmunotherapy Clinical use · New analytes
University of Minnesota Minneapolis, MN
umn.edu Universities & research institutes Public research university in Minneapolis and Saint Paul, Minnesota, with medical and veterinary schools.	Poster Part of Poster sessions Single-cell Profiling of Liquid Biopsy Cells Associated with Cancer Risk Reveals Increased Inferred Copy Number Variation Early detection · New analytes Poster Part of Poster sessions Integration of the Shine on Suspicion Test and eBAT Interventional Therapy for Canine Cancer Prevention Early detection Poster Part of Poster sessions Disentangling Biological Signal from Technical Noise in Multi-matrix Cell-free DNA Profiling of Canine Diffuse Large B-cell Lymphoma Pre-analytics · ctDNA & MRD Poster Part of Poster sessions Test and Intervene: a Strategic Framework for Liquid Biopsy-guided Cancer Prevention Early detection
GENYO Granada, Spain
genyo.es Universities & research institutes Genomics and oncology research centre run jointly by Pfizer, the University of Granada and the Andalusian regional government.	Talk Sun Nov 8 5:30pm–6:30pm Part of Young Career Session Summary of ISLB YC 2026 Activities Poster Part of Poster sessions Dynamic Circulating Tumour Cell Phenotypes and Circulating Tumour DNA Evolution During PARP Inhibitor Therapy in High-grade Serous Ovarian Cancer New analytes · ctDNA & MRD Poster Part of Poster sessions Comparative Evaluation of two Automated Magnetic-bead cell free DNA Extraction Workflows in Early Colorectal Cancer Pre-analytics
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12) Madrid, Spain
imas12.es Universities & research institutes Health research institute of the 12 de Octubre University Hospital in Madrid.	Poster Part of Poster sessions "HER2 in Plasma Small Extracellular Vesicles for Monitoring Response to Trastuzumab Deruxtecan in Advanced Breast Cancer" New analytes · Clinical use Poster Part of Poster sessions Influence of Macrophage Polarization on Tumor Hybrid Cell Formation in Different Co-culture Models with Bladder Cancer Cell Lines New analytes Poster Part of Poster sessions Peripheral Immune Profiling by Multiparametric Flow Cytometry in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Deruxtecan Clinical use · New analytes Collaborators: Hospital Universitario 12 de Octubre
Ohio State University Columbus, OH
osu.edu Universities & research institutes Public research university in Columbus, Ohio, with a college of medicine and a comprehensive cancer center.	Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Talk Sun Nov 8 1:30pm–3:00pm Part of Tumor Type Related MRD and Hematologic Malignancies Clinical use Talk Sun Nov 8 5:30pm–6:30pm Part of Young Career Session Summary of ISLB YC 2026 Activities
Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh, India
pgimer.edu.in Universities & research institutes Public medical school, hospital and research institute in Chandigarh, India.	Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Transcriptomic Profiling of Circulating Tumour Cells Identifies High-Risk Metastatic Programs and Predicts Recurrence in Oral Squamous Cell Carcinoma Poster Part of Poster sessions Single-cell Profiling of PBMCs Reveals Immune Expression Programs Associated with Presence of Circulating Tumour Cells in Oral Squamous Cell Carcinoma New analytes Poster Part of Poster sessions Circulating Tumour Cell Profiling Integrated with Spatial Transcriptomics Reveals Predictors of Early Recurrence in Oral Squamous Cell Carcinoma New analytes · Clinical use
Sapienza University of Rome Rome, Italy
uniroma1.it Universities & research institutes Public university in Rome, Italy, with faculties of medicine and teaching hospitals.	Session Sat Nov 7 9:45am–11:15am Evolving and Future Methodologies in Liquid Biopsy: CTCs, Tumor Vesicles and Emerging Approaches New analytes Poster Part of Poster sessions Organotropism-Specific CTC Morphology and Heterotypic Clustering Predict Metastatic Site in Solid Tumors New analytes Collaborators: Link Campus University Poster Part of Poster sessions Circulating microRNA Signatures are Immunotherapy Response and Prognostic Biomarkers in Recurrent/Metastatic Head and Neck Patients New analytes · Clinical use